Double Negative (IgG+IgD-CD27-) B cells are increased in a cohort of moderate-severe Alzheimer's disease patients and show a pro-inflammatory trafficking receptor phenotype

Journal of Alzheimer's Disease

Volumn 44, Issue 4, 2015, Pages 1241-1251

  Bulati, Matteo ^a   Martorana, Adriana ^a   Gervasi, Francesco ^b   Camarda, Cecilia ^a   Azzarello, Delia Maria ^a   Monastero, Roberto ^a   Caruso, Calogero ^a   Colonna Romano, Giuseppina ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Dipartimento di Neuroscienze   (Italy)

Author keywords

Aging; Alzheimer's disease; B cells; CCR6; CCR7; trafficking profile

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CD27 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; CCR6 PROTEIN, HUMAN; CCR7 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL SUBPOPULATION; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; INFLAMMATION; MEDIATOR RELEASE; MEMORY CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; VERY ELDERLY; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; MALE; MENTAL HEALTH; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIGENS, CD27; B-LYMPHOCYTE SUBSETS; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; MALE; MENTAL STATUS SCHEDULE; PHENOTYPE; RECEPTORS, CCR6; RECEPTORS, CCR7;

EID: 84923277241     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142412     Document Type: Article

References (69)

1. Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. (2013) The worldwide economic impact of dementia 2010. Alzheimers Dement 9, 1-11.e3.
2. de Vugt ME, Verhey FR (2013) The impact of early dementia diagnosis and intervention on informal caregivers. Prog Neurobiol 110, 54-62.
3. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: Neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8, 142-150.
4. Broussard GJ, Mytar J, Li RC, Klapstein GJ (2012) The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology 20, 109-126.
5. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS (2004) Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNKdependent MAPK pathway. J Biol Chem 279, 49523-49532.
6. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J (2008) Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5, 51.
7. Griffin WS (2006) Inflammation and neurodegenerative diseases. Am J Clin Nutr 83, 470S-474S.
8. Reale M, Iarlori C, Feliciani C, Gambi D (2008) Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 14, 147-159.
9. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69, 1034-1043.
10. Britschgi M, Wyss-Coray T (2007) Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 82, 205-233.
11. Goldeck D, Larbi A, Pellicanó M, Alam I, Zerr I, Schmidt C, Fulop T, Pawelec G (2013) Enhanced chemokine receptor expression on leukocytes of patients with Alzheimer's disease. PLoS One 8, e66664.
12. Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G (2013) Elusive Alzheimer's disease: Can immune signatures help our understanding of this challenging disease? Part 1: Clinical and historical background. Discov Med 15, 23-32.
13. Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G (2013) Elusive Alzheimer's disease: Can immune signatures help our understanding of this challenging disease? Part 2: New immune paradigm. Discov Med 15, 33-42.
14. Town T, Tan J, Flavell RA, Mullan M (2005) T-cells in Alzheimer's disease. Neuromolecular Med 7, 255-264.
15. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH (2009) Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 182, 5778-5788.
16. Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 28, 1163-1169.
17. Ciccocioppo F, Lanuti P, Marchisio M, Gambi F, Santavenere E, Pierdomenico L, Bascelli A, Velluto L, Gambi D, Miscia S (2008) Expression and phosphorylation of protein kinase C isoforms in Abeta (1-42) activated T lymphocytes from Alzheimers disease. Int J Immunopathol Pharmacol 21, 23-33.
18. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T (2009) Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 17, 91-103.
19. Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, Li B, Fang WG, Zhu L, Chen YH (2010) Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging 31, 175-188.
20. Pellicanò M, Bulati M, Buffa S, Barbagallo M, Di Prima A, Misiano G, Picone P, Di Carlo M, Nuzzo D, Candore G, Vasto S, Lio D, Caruso C, Colonna-Romano G (2010) Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. J Alzheimers Dis 21, 181-192.
21. PellicanòM, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, Pawelec G (2012) Immune profiling of Alzheimer patients. J Neuroimmunol 242, 52-59.
22. Martorana A, Bulati M, Buffa S, Pellicanò M, Caruso C, Candore G, Colonna-Romano G (2012) Immunosenescence, inflammation and Alzheimer's disease. Longev Healthspan 1, 8.
23. Józwik A, Landowski J, Bidzan L, Fülop T, Bryl E, Witkowski JM (2012) Beta-amyloid peptides enhance the proliferative response of activated CD4+CD28+lymphocytes from Alzheimer disease patients and from healthy elderly. PLoS One 7, e33276.
24. Bulati M, Buffa S, Martorana A, Candore G, Lio D, Caruso C, Colonna-Romano (2014) Trafficking phenotype and production of granzyme B by double negative B cells (IgG (+)IgD (-)CD27 (-)) in the elderly. Exp Gerontol 54, 123-129.
25. Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio D, Candore G, Caruso C (2009) A doublenegative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Develop 130, 681-690.
26. Buffa S, Bulati M, Pellicanò M, Dunn-Walters DK, Wu YC, Candore G, Vitello S, Caruso C, Colonna-Romano G (2011) B cell immunosenescence: Different features of naive and memory B cells in elderly. Biogerontology 12, 473-483.
27. Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicanò M, Wu YC, Colonna Romano G (2011) B cells and immunosenescence: A focus on IgG+IgD-CD27- (DN) B cells in aged humans. Ageing Res Rev 10, 274-284.
28. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner ECB, Sanz I (2007) A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178, 6624-6633.
29. Sanz I, Wei C, Lee FE, Anolik J (2008) Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20, 67-82.
30. Cagigi A, Du L, Dang LV, Grutzmeier S, Atlas A, Chiodi F, Pan-Hammarström Q, Nilsson A (2009) CD27 (-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection. PLoS One 4, e5427.
31. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I (2012) Advances in human B cell phenotypic profiling. Front Immunol 3, 302-316.
32. Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, Turvey M, Brazzatti J, Gregor C, Nguyen P, Kara E, McColl SR (2010) An immune paradox: How can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: A chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 32, 1067-1076.
33. Welsh-Bacic D, Lindenmeyer M, Cohen CD, Draganovici D, Mandelbaum J, Edenhofer I, Ziegler U, Regele H, Wüthrich RP, Segerer S (2011) Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrol Dial Transplant 26, 1211-1220.
34. Müller G, Lipp M (2003) Shaping up adaptive immunity: The impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation 10, 325-334.
35. McNamee EN, Masterson JC, Jedlicka P, Collins CB, Williams IR, Rivera-Nieves J (2013) Ectopic lymphoid tissue alters the chemokine gradient, increases lymphocyte retention and exacerbates murine ileitis. Gut 62, 53-62.
36. American Psychiatric Association. (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV (Text Revision). American Psychiatric Association, Washington, DC.
37. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
38. Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9 (Suppl 1), 173-176.
39. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 48, 189-198.
40. Rikkert MG, Tona KD, Janssen L, Burns A, Lobo A, Robert P, Sartorius N, Stoppe G, Waldemar G (2011) Validity, reliability, and feasibility of clinical staging scales in dementia: A systematic review. Am J Alzheimers Dis Other Demen 26, 357-365.
41. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
42. Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D (2004) Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the proinflammatory and anti-inflammatory cytokines. J Neuroimmunol 148, 162-171.
43. Carlesimo GA, Caltagirone C, Gainotti G (1996) The mental deterioration battery: Normative data, diagnostic reliability and quantitative analyses of cognitive impairment. Eur Neurol 36, 378-384.
44. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 185, 914-919.
45. Parmelee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 43, 130-137.
46. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G (2011) Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 11, 149-153.
47. Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, Garagnani P, Giuliani C, Fontanesi E, Ostan R, Bucci L, Sevini F, Yani SL, Barbieri A, Lomartire L, Borelli V, Vianello D, Bellavista E, Martucci M, Cevenini E, Pini E, Scurti M, Biondi F, Santoro A, Capri M, Franceschi C (2013) Immune system, cell senescence, aging and longevity-inflamm-aging reappraised. Curr Pharm Des 19, 1675-1679.
48. Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C (2008) Association between the interleukin-1beta polymorphisms and Alzheimer's disease: A systematic review and meta-analysis. Brain Res Rev 59, 155-163.
49. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Cammá; C, Lio D, Caruso C (2009) Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 61, 60-68.
50. Di Bona D, Scapagnini G, Candore G, Castiglia L, Colonna-Romano G, Duro G, Nuzzo D, Iemolo F, Lio D, PellicanòM, Scafidi V, Caruso C, Vasto S (2010) Immune-inflammatory responses and oxidative stress in Alzheimer's disease: Therapeutic implications. Curr Pharm Des 16, 684-691.
51. Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C (2012) Association between interleukin-10 polymorphisms and Alzheimer's disease: A systematic review and metaanalysis. J Alzheimers Dis 29, 751-759.
52. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678.
53. Monsonego A, Nemirovsky A, Harpaz I (2013) CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology 139, 438-446.
54. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid-peptide. Nat Rev Mol Cell Biol 8, 101-112.
55. Walsh DM, Selkoe DJ (2007) A oligomers-a decade of discovery. J Neurochem 101, 1172-1184.
56. Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE (2012) Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2, a009381.
57. Rodrigues MC, Sanberg PR, Cruz LE, Garbuzova-Davis S (2014) The innate and adaptive immunological aspects in neurodegenerative diseases. J Neuroimmunol 269, 1-8.
58. Licastro F, Carbone I, Ianni M, Porcellini E (2011) Gene signature in Alzheimer's disease and environmental factors: The virus chronicle. J Alzheimers Dis 27, 809-817.
59. Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, YongVW, Nuttall RK, Pennington CJ, Edwards DR, Bar-OrA (2003) Determinants of human B cell migration across brain endothelial cells. J Immunol 170, 4497-4505.
60. Sallusto F, Impellizzieri D, Basso C, Laroni A, Uccelli A, Lanzavecchia A, Engelhardt B (2012) T-cell trafficking in the central nervous system. Immunol Rev 248, 216-227.
61. Subramanian S, Ayala P, Wadsworth TL, Harris CJ, Vandenbark AA, Quinn JF, Offner H (2010) CCR6: A biomarker for Alzheimer's-like disease in a triple transgenic mouse model. J Alzheimers Dis 22, 619-629.
62. Agrawal S, Gupta S (2011) TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 31, 89-98.
63. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3, 944-950.
64. Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubartelli A, Cozzolino F, Aloe L, Garaci E (1996) Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85, 345-356.
65. Wirths S, LanzavecchiaA (2005)ABCB1transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 35, 3433-3441.
66. Hagn M, Jahrsdörfer B (2012) Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. Oncoimmunol 1, 1368-1375.
67. Glass WG, Lane TE (2003) Functional expression of chemokine receptor CCR5 on CD4 (+) T cells during virusinduced central nervous system disease. J Virol 77, 191-198.
68. Lee YK, Kwak DH, Oh KW, Nam SY, Lee BJ, Yun YW, Kim YB, Han SB, Hong JT (2009) CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol Learn Mem 92, 356-363.
69. Sorce S, Myburgh R, Krause KH (2011) The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93, 297-311.